dc.contributor.author | Oza, B | |
dc.contributor.author | Eisen, T | |
dc.contributor.author | Frangou, E | |
dc.contributor.author | Stewart, GD | |
dc.contributor.author | Bex, A | |
dc.contributor.author | Ritchie, AWS | |
dc.contributor.author | Kaplan, R | |
dc.contributor.author | Smith, B | |
dc.contributor.author | Davis, ID | |
dc.contributor.author | Stockler, MR | |
dc.contributor.author | Albiges, L | |
dc.contributor.author | Escudier, B | |
dc.contributor.author | Larkin, J | |
dc.contributor.author | Joniau, S | |
dc.contributor.author | Hancock, B | |
dc.contributor.author | Hermann, GG | |
dc.contributor.author | Bellmunt, J | |
dc.contributor.author | Parmar, MKB | |
dc.contributor.author | Royston, P | |
dc.contributor.author | Meade, A | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2022-08-19T10:36:51Z | |
dc.date.available | 2022-08-19T10:36:51Z | |
dc.date.issued | 2022-06-01 | |
dc.identifier.citation | Journal of Clinical Oncology, 2022, 40 (16), pp. 1772 - 1782 | en_US |
dc.identifier.issn | 0732-183X | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5282 | |
dc.identifier.eissn | 1527-7755 | |
dc.identifier.eissn | 1527-7755 | |
dc.identifier.doi | 10.1200/JCO.21.01090 | |
dc.description.abstract | PURPOSE: The 2003 Leibovich score guides prognostication and selection to adjuvant clinical trials for patients with locally advanced renal cell carcinoma (RCC) after nephrectomy. We provide a robust external validation of the 2003 Leibovich score using contemporary data from SORCE, an international, randomized trial of sorafenib after excision of primary RCC. METHODS: Data used to derive the 2003 Leibovich score were compared with contemporary data from SORCE. Discrimination and calibration of the metastasis-free survival outcome were assessed in data from patients with clear-cell RCC, using Cox proportional hazards regression, Kaplan-Meier curves, and calculation of Harrell's c indexes. Secondary analyses involved three important SORCE groups: patients with any non-clear-cell subtype, papillary, and chromophobe carcinomas. RESULTS: Four hundred seven recurrences occurred in 982 patients in the Leibovich cohort and 520 recurrences were recorded in 1,445 patients in the primary SORCE cohort. Clear discrimination between intermediate-risk and high-risk SORCE cohorts was shown; hazard ratio 2.74 (95% CI, 2.29 to 3.28), c-index 0.63 (95% CI, 0.61 to 0.65). A hazard ratio of 0.61 (95% CI, 0.53 to 0.70) confirmed poor calibration of the two cohorts. Discrimination was observed in secondary populations, with c-indexes of 0.64 (95% CI, 0.59 to 0.69) for non-clear-cell RCC, 0.63 (95% CI, 0.56 to 0.69) for papillary RCC, and 0.65 (95% CI, 0.55 to 0.76) for chromophobe RCC. CONCLUSION: The 2003 Leibovich score discriminates between intermediate-risk and high-risk clear-cell and non-clear-cell RCC groups in contemporary data, supporting its use for risk stratification in adjuvant clinical trials. Over time, metastasis-free survival for patients with locally advanced RCC has improved. Contemporary data from adjuvant RCC trials should be used to improve prognostication for patients with RCC. | |
dc.format | Print-Electronic | |
dc.format.extent | 1772 - 1782 | |
dc.language | eng | |
dc.language.iso | eng | en_US |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | en_US |
dc.relation.ispartof | Journal of Clinical Oncology | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | en_US |
dc.subject | Carcinoma, Renal Cell | |
dc.subject | Humans | |
dc.subject | Kidney Neoplasms | |
dc.subject | Nephrectomy | |
dc.subject | Prognosis | |
dc.subject | Recurrence | |
dc.subject | Sorafenib | |
dc.title | External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. | en_US |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-01-20 | |
dc.date.updated | 2022-08-19T10:35:35Z | |
rioxxterms.version | VoR | en_US |
rioxxterms.versionofrecord | 10.1200/JCO.21.01090 | en_US |
rioxxterms.licenseref.startdate | 2022-06-01 | |
rioxxterms.type | Journal Article/Review | en_US |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/35213214 | |
pubs.issue | 16 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
pubs.publication-status | Published | |
pubs.volume | 40 | |
dc.contributor.icrauthor | Larkin, James | |
icr.provenance | Deposited by Mr Arek Surman (impersonating Prof James Larkin) on 2022-08-19. Deposit type is initial. No. of files: 1. Files: External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase II.pdf | |